• financing

Capital procurement through third-party allotment of shares.

Celaid Therapeutics implemented a third-party allotment of shares with The University of Tokyo Edge Capital Partners Co., Ltd. (Bunkyo-ku, Tokyo, President and Managing Partner, Tomotaka Goji).

This capital procurement will promote the development of our technologies and will allow us to accelerate the development of new therapies.

Copyright© セレイドセラピューティクス - 細胞治療(造血幹細胞) , 2024 All Rights Reserved Powered by STINGER.